Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator

被引:12
作者
Daimee, Usama A. [1 ]
Vermilye, Katherine [1 ]
Moss, Arthur J. [1 ]
Goldenberg, Ilan [1 ]
Klein, Helmut U. [1 ]
McNitt, Scott [1 ]
Zareba, Wojciech [1 ]
Kutyifa, Valentina [1 ]
机构
[1] Univ Rochester, Med Ctr, Div Cardiol, Heart Res Follow Up Program, 265 Crittenden Blvd,Box 653, Rochester, NY 14642 USA
关键词
Compliance; Implantable cardioverter-defibrillator; Older patients; Ventricular tachyarrhythmias; Wearable cardioverter-defibrillator; ACUTELY TERMINATING EPISODES; HIGH-RISK; VENTRICULAR-FIBRILLATION; ATRIAL-FIBRILLATION; CLINICAL-EFFICACY; DYSFUNCTION; INFARCTION; THERAPY; SHOCKS;
D O I
10.1016/j.hrthm.2018.04.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Use of the wearable cardioverter-defibrillator (WCD) in older patients has not been described previously. OBJECTIVE The purpose of this study was to assess WCD wear time, risk of arrhythmic events during WCD use, and implantable cardioverter-defibrillator (ICD) implantation rates after the end of WCD use in patients with age >= 65 years vs <65 years. METHODS We stratified 1732 patients with ischemic and nonischemic cardiomyopathy from the Prospective Registry of Patients Using the Wearable Defibrillator Registry into 2 subgroups by age: those with age >= 65 years and those with age <65 years. Wear time, arrhythmic events, and end-of-use decisions, specifically ICD implantation or improvement in ejection fraction, were evaluated for each age group. RESULTS There were 722 patients with age >= 65 years (41.7%) and 1010 patients with age <65 years (58.3%). Daily WCD wear time was longer in the older population (median 22.8 h/d (IQR 21.5 23.2) vs 22.3 h/d (IQR 19.5- 23.0); P <.001). Patients with age >= 65 years experienced higher event rates, per 100 patient-years, for any sustained ventricular tachycardia/ventricular fibrillation (31.95 vs 9.82; P =.027) and ventricular tachycardia/ventricular fibrillation treated with WCD shock (6.92 vs 2.37; P =.034), particularly with ischemic cardiomyopathy. Younger patients experienced a trend toward a higher event rate for atrial arrhythmias with nonischemic cardiomyopathy (150.07 vs 74.86; P =.055). At the end of WCD use, ICD implantation was more frequent in older patients (41.8% vs 36.5%; P =.034). CONCLUSION Older patients had good compliance with the WCD, presented with more frequent ventricular arrhythmias, and were more likely to receive an ICD at the end of WCD use. The WCD may play a role in risk stratification of the older population.
引用
收藏
页码:1379 / 1386
页数:8
相关论文
共 50 条
  • [31] Extended Use of the Wearable Cardioverter-Defibrillator: Which Patients Are Most Likely to Benefit?
    Kovacs, Boldizsar
    Reek, Sven
    Krasniqi, Nazmi
    Eriksson, Urs
    Duru, Firat
    CARDIOLOGY RESEARCH AND PRACTICE, 2018, 2018
  • [32] The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up
    Rosenkaimer, Stephanie L.
    El-Battrawy, Ibrahim
    Dreher, Tobias C.
    Gerhards, Stefan
    Roeger, Susanne
    Kuschyk, Juergen
    Borggrefe, Martin
    Akin, Ibrahim
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (03)
  • [33] The implantable cardioverter-defibrillator
    Greene, HL
    CLINICAL CARDIOLOGY, 2000, 23 (05) : 315 - 326
  • [34] Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry (2020)
    Veltmann, Christian
    Winter, Stefan
    Duncker, David
    Jungbauer, Carsten G.
    Waessnig, Nadine K.
    Geller, J. Christoph
    Erath, Julia W.
    Goeing, Olaf
    Perings, Christian
    Ulbrich, Michael
    Roser, Mattias
    Husser, Daniela
    Gansera, Laura S.
    Soezener, Korkut
    Malur, Frank Michael
    Block, Michael
    Fetsch, Thomas
    Kutyifa, Valentina
    Klein, Helmut U.
    CLINICAL RESEARCH IN CARDIOLOGY, 2021, 110 (01) : 151 - 151
  • [35] Patients with Pacemaker or Implantable Cardioverter-Defibrillator
    Schulman, Peter M.
    Rozner, Marc A.
    Sera, Valerie
    Stecker, Eric C.
    MEDICAL CLINICS OF NORTH AMERICA, 2013, 97 (06) : 1051 - +
  • [36] How Should We Use the Wearable Cardioverter-Defibrillator in Japan?
    Shimizu, Akihiko
    CIRCULATION JOURNAL, 2014, 78 (12) : 2851 - 2853
  • [37] Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication
    Schaer, Beat
    Kuehne, Michael
    Reichlin, Tobias
    Osswald, Stefan
    Sticherling, Christian
    EUROPACE, 2016, 18 (02): : 227 - 231
  • [38] Primary prevention of sudden cardiac death through a wearable cardioverter-defibrillator
    Gabrielli, Domenico
    Benvenuto, Manuela
    Baroni, Matteo
    Oliva, Fabrizio
    Capucci, Alessandro
    GIORNALE ITALIANO DI CARDIOLOGIA, 2015, 16 (07) : 418 - 425
  • [39] First human safety and effectiveness study of defibrillation with a novel patch wearable cardioverter-defibrillator
    Chovanec, Milan
    Petru, Jan
    Hala, Pavel
    Kralovec, Stepan
    Thakkar, Anjali B.
    Mathews, Kiran
    Dinger, Maarten
    Ullery, Steven
    Eapen, Zubin J.
    Kumar, Uday N.
    Neuzil, Petr
    EUROPACE, 2024, 26 (07):
  • [40] Indications for and outcome in patients with the wearable cardioverter-defibrillator in a nurse-based training programme: results of the Austrian WCD Registry
    Odeneg, Tanja
    Ebner, Christian
    Moertl, Deddo
    Keller, Hans
    Dirninger, Alfred
    Stix, Guenter
    Foeger, Bernhard
    Grimm, Georg
    Steinwender, Clemens
    Gebetsberger, Franz
    Stuehlinger, Markus
    Mastnak, Bernadette
    Haider, Christian
    Manninger, Martin
    Scherr, Daniel
    EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2019, 18 (01) : 75 - 83